TY - JOUR T1 - The preventive effect of recombinant human hepatocyte growth factor for hepatic steatosis in a rat model of short bowel syndrome. AU - Yano,Keisuke, AU - Sugita,Koshiro, AU - Muto,Mitsuru, AU - Matsukubo,Makoto, AU - Onishi,Shun, AU - Kedoin,Chihiro, AU - Matsui,Mayu, AU - Murakami,Masakazu, AU - Harumatsu,Toshio, AU - Yamada,Koji, AU - Yamada,Waka, AU - Kumagai,Kotaro, AU - Ido,Akio, AU - Kaji,Tatsuru, AU - Ieiri,Satoshi, Y1 - 2022/03/13/ PY - 2022/02/06/received PY - 2022/02/23/accepted PY - 2022/4/10/pubmed PY - 2022/6/16/medline PY - 2022/4/9/entrez KW - Farnesoid X receptor KW - Gut micro biota KW - Hepatic steatosis KW - Intestinal failure associated liver disease KW - Short bowel syndrome KW - Toll-like receptor 4 SP - 1286 EP - 1292 JF - Journal of pediatric surgery JO - J Pediatr Surg VL - 57 IS - 7 N2 - PURPOSE: Short bowel syndrome (SBS) patients require total parenteral nutrition (TPN) following massive small bowel resection (SBR), which may cause intestinal failure-associated liver disease (IFALD), a life-threatening complication. Hepatocyte growth factor (HGF) acts as a potent hepatocyte mitogen with anti inflammatory and antioxidant actions. The present study evaluated the effect of recombinant human HGF (rh-HGF) on SBR and subsequent IFALD using a parentally fed rat model of SBS. METHODS: Rats underwent jugular vein catheterization for continuous TPN and 90% SBR. They were divided into 2 groups: TPN alone (SBS/TPN group: n = 7) or TPN plus the intravenous administration of rh-HGF (0.3 mg/kg/day) (SBS/TPN+HGF group: n = 7). On day 7, their tissues and stool were harvested to evaluate the effects of HGF. RESULTS: Regarding the histological findings, based on the nonalcoholic fatty liver disease (NAFLD) activity score, the SBS/TPN+HGF group showed significantly less hepatic steatosis and inflammatory cell infiltration than the SBS/TPN group (NAFLD activity score, 4.00 ± 1.83 vs. 1.00 ± 0.82; p < 0.01). The SBS/TPN+HGF group showed a higher expression of Farnesoid X receptor in the liver and lower expression of Toll-like receptor 4 in the ileum than the SBS/TPN group. Regarding the composition of the bacterial gut microbiota, Actinobacteria, Bacteroidetes and Proteobacteria were decreased in the SBS/TPN+HGF group compared with the SBS/TPN group. CONCLUSION: In our SBS with TPN rat model, rh-HGF administration had a preventive effect against hepatic steatosis and dysbiosis. rh-HGF may therefore be a potentially effective therapeutic agent for SBS and subsequent IFALD. TYPE OF STUDY: Experimental research. SN - 1531-5037 UR - https://www.unboundmedicine.com/medline/citation/35396090/The_preventive_effect_of_recombinant_human_hepatocyte_growth_factor_for_hepatic_steatosis_in_a_rat_model_of_short_bowel_syndrome_ DB - PRIME DP - Unbound Medicine ER -